TWi Biotechnology, Inc.
Taipei Exchange 6610.TWO
TWi Biotechnology, Inc. Price to Earnings Ratio (P/E) on January 14, 2025: -6.59
-
TWi Biotechnology, Inc. 52-week high Price to Earnings Ratio (P/E) is -5.55 on April 22, 2024, which is 15.79% above the current Price to Earnings Ratio (P/E).
-
TWi Biotechnology, Inc. 52-week low Price to Earnings Ratio (P/E) is -7.79 on July 16, 2024, which is -18.22% below the current Price to Earnings Ratio (P/E).
-
TWi Biotechnology, Inc. average Price to Earnings Ratio (P/E) for the last 52 weeks is -6.68.
| Date | Price to Earnings Ratio (P/E) | Price to Sales Ratio (P/S) | Price to Book Ratio (P/B) | Dividend Yield |
|---|
| CEO | Ms. Yijun Wu |
| IPO Date | Dec. 27, 2016 |
| Location | |
| Headquarters | No. 41, Lane 221 |
| Employees | 21 |
| Sector | Health Care |
| Industries | |
TWi Biotechnology, Inc., a clinical-stage biopharmaceutical company, develops and sells drugs for innate immunity-related diseases in Taiwan. The company development pipeline comprises AC-203, which is in Phase 2 clinical trial for various indications, including epidermolysis bullosa simplex, epidermolysis bullosa, arthritis, gout, and diabetes mellitus; and AC- 1101, which is in Phase 1 trial for the treatment of vitiligo and preclinical stage for the treatment of atopic dermatitis, as well as granuloma annulare and rare autoimmune skin diseases. It has a drug development agreement with Hong Kong Winhealth Pharma Group Co., Limited. in Mainland China, Hong Kong, and Macao markets. TWi Biotechnology, Inc. was founded in 2010 and is based in Taipei, Taiwan.
Past 5 years
StockViz Staff
January 15, 2025
Any question? Send us an email